Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. [electronic resource]
Producer: 20120906Description: 700-5 p. digitalISSN:- 1476-5365
- Adult
- Aged
- Alemtuzumab
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Cyclophosphamide -- therapeutic use
- Female
- Graft Survival
- Graft vs Host Disease -- prevention & control
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Male
- Middle Aged
- Reoperation
- Retrospective Studies
- Salvage Therapy -- methods
- Transplantation Conditioning -- methods
- Transplantation, Homologous -- adverse effects
- Vidarabine -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.